Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Safety and Efficacy of Adebrelimab Combined With SOX Regimen in Preoperative Neoadjuvant Therapy for Locally Advanced Gastric Adenocarcinoma Patients (ASOG-01)

Next Previous
Search
Trial Profile

The Safety and Efficacy of Adebrelimab Combined With SOX Regimen in Preoperative Neoadjuvant Therapy for Locally Advanced Gastric Adenocarcinoma Patients (ASOG-01)

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 06 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adebrelimab (Primary) ; Gimeracil/oteracil/tegafur; Oxaliplatin
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Acronyms ASOG-01

Most Recent Events

  • 26 Jan 2024 According to ClinicalTrials.gov record, protocol has been amended to increase patient number from 72 to 110. Also the Primary endpoint has been updated and the overall trial focus has been changed to TU.
  • 26 Jan 2024 Planned number of patients changed from 72 to 110.
  • 26 Jan 2024 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top